---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-033616"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:49:47.222736+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton Q3 product sales $22.5M (+129% YoY), non-GAAP EPS $0.04, ET-600 PDUFA Feb 2026

## Summary
- Product sales of $22.5M, up 129% YoY; 19th consecutive quarter of sequential growth.
- GAAP EPS loss $0.07; non-GAAP diluted EPS $0.04; Adjusted EBITDA $2.9M.
- ET-600 NDA accepted with PDUFA date February 25, 2026; launch production scheduled.
- INCRELEX largest revenue contributor; GALZIN exceeded year-end target of 200 active patients.
- Generated $12.0M cash from operations; ending cash balance $37.1M.

## SEC filing metadata
- accession: 0001437749-25-033616
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/0001437749-25-033616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/eton20250819_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-033616
- JSON: https://secwatch.observer/filing/0001437749-25-033616.json
- Plain text: https://secwatch.observer/filing/0001437749-25-033616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.